The Experts below are selected from a list of 166245 Experts worldwide ranked by ideXlab platform
Douglas A Jabs - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the united states Public Health Service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis
American Journal of Ophthalmology, 2011Co-Authors: Janet T Holbrook, Ryan Colvin, Mark L Van Natta, Jennifer E Thorne, Mark Bardsley, Douglas A JabsAbstract:Purpose To evaluate United States Public Health Service (USPHS) guidelines for discontinuing anticytomegalovirus (CMV) therapy in patients with AIDS who have immune recovery and quiescent retinitis after initiating highly active antiretroviral therapy. Design Cohort study of patients with CMV retinitis (Longitudinal Study of Ocular Complications of AIDS). Methods Participants had CMV retinitis and CD4+ T-cell counts of 50 cells/μL or fewer enrolled from 1998 through 2009 who demonstrated sustained immune recovery (2 consecutive CD4+ T-cell counts of 100 cells/μL or more at least 6 months apart) and inactive retinitis. Participants were classified into 2 groups according to anti-CMV treatment after immune recover: (1) continued anti-CMV therapy and (2) discontinued therapy. We evaluated survival, visual acuity, and CMV retinitis activity; we used propensity scores to adjust for confounding factors for these analyses. Results Of 152 participants reviewed, 71 demonstrated immune recovery, 37 of whom discontinued therapy and 34 of whom continued therapy. At immune recovery, participants continuing therapy tended to be older (44 vs 40 years; P = .09), have bilateral retinitis (53% vs 32%; P = .10), and have lower CD4+ T-cell counts (148 vs 207 cells/μL; P P Conclusions Discontinuation of anti-CMV therapy after immune recovery did not increase the risk of poor outcomes. These results support the current guidelines for discontinuation of anti-CMV therapy after achievement of sustained immune recovery.
A.j. Rush - One of the best experts on this subject based on the ideXlab platform.
-
clinical practice guidelines for managing major depression in primary care practice implications for psychologists u s Public Health Service agency for Health care policy and research
American Psychologist, 1994Co-Authors: Herbert C Schulberg, A.j. RushAbstract:: Clinical practice guidelines are being developed by professional and governmental bodies to improve the quality of Health care. The guidelines developed by the U.S. Public Health Service Agency for Health Care Policy and Research seek to improve the primary care physician's ability to diagnose and treat major depression. Clinical, educational, and research implications for psychologists are considered in light of how the recommended guidelines potentially will influence the nature and quality of care provided for mood disorders by generalist physicians.
Dependence Update Panel - One of the best experts on this subject based on the ideXlab platform.
-
a clinical practice guideline for treating tobacco use and dependence 2008 update a u s Public Health Service report
American Journal of Preventive Medicine, 2008Co-Authors: Dependence Update PanelAbstract:Objective To summarize the U.S. Public Health Service guideline Treating Tobacco Use and Dependence: 2008 Update, which provides recommendations for clinical interventions and system changes to promote the treatment of tobacco dependence. Participants An independent panel of 24 scientists and clinicians selected by the U.S. Agency for Healthcare Research and Quality on behalf of the U.S. Public Health Service. A consortium of eight governmental and nonprofit organizations sponsored the update. Evidence Approximately 8700 English-language, peer-reviewed articles and abstracts, published between 1975 and 2007, were reviewed for data that addressed assessment and treatment of tobacco dependence. This literature served as the basis for more than 35 meta-analyses. Consensus process Two panel meetings and numerous conference calls and staff meetings were held to evaluate meta-analyses and relevant literature, to synthesize the results, and to develop recommendations. The updated guideline was then externally reviewed by more than 90 experts, made available for Public comment, and revised. Conclusions This evidence-based, updated guideline provides specific recommendations regarding brief and intensive tobacco-cessation interventions as well as system-level changes designed to promote the assessment and treatment of tobacco use. Brief clinical approaches for patients willing and unwilling to quit are described.
Herbert C Schulberg - One of the best experts on this subject based on the ideXlab platform.
-
clinical practice guidelines for managing major depression in primary care practice implications for psychologists u s Public Health Service agency for Health care policy and research
American Psychologist, 1994Co-Authors: Herbert C Schulberg, A.j. RushAbstract:: Clinical practice guidelines are being developed by professional and governmental bodies to improve the quality of Health care. The guidelines developed by the U.S. Public Health Service Agency for Health Care Policy and Research seek to improve the primary care physician's ability to diagnose and treat major depression. Clinical, educational, and research implications for psychologists are considered in light of how the recommended guidelines potentially will influence the nature and quality of care provided for mood disorders by generalist physicians.
Jennifer E Thorne - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the united states Public Health Service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis
American Journal of Ophthalmology, 2011Co-Authors: Janet T Holbrook, Ryan Colvin, Mark L Van Natta, Jennifer E Thorne, Mark Bardsley, Douglas A JabsAbstract:Purpose To evaluate United States Public Health Service (USPHS) guidelines for discontinuing anticytomegalovirus (CMV) therapy in patients with AIDS who have immune recovery and quiescent retinitis after initiating highly active antiretroviral therapy. Design Cohort study of patients with CMV retinitis (Longitudinal Study of Ocular Complications of AIDS). Methods Participants had CMV retinitis and CD4+ T-cell counts of 50 cells/μL or fewer enrolled from 1998 through 2009 who demonstrated sustained immune recovery (2 consecutive CD4+ T-cell counts of 100 cells/μL or more at least 6 months apart) and inactive retinitis. Participants were classified into 2 groups according to anti-CMV treatment after immune recover: (1) continued anti-CMV therapy and (2) discontinued therapy. We evaluated survival, visual acuity, and CMV retinitis activity; we used propensity scores to adjust for confounding factors for these analyses. Results Of 152 participants reviewed, 71 demonstrated immune recovery, 37 of whom discontinued therapy and 34 of whom continued therapy. At immune recovery, participants continuing therapy tended to be older (44 vs 40 years; P = .09), have bilateral retinitis (53% vs 32%; P = .10), and have lower CD4+ T-cell counts (148 vs 207 cells/μL; P P Conclusions Discontinuation of anti-CMV therapy after immune recovery did not increase the risk of poor outcomes. These results support the current guidelines for discontinuation of anti-CMV therapy after achievement of sustained immune recovery.